Shanghai Saibiman Biotechnology

Cellular Biomedicine Group (CBMG) is a clinical-stage biopharmaceutical company specializing in the development of proprietary cell therapies for cancer and degenerative diseases. The company's portfolio includes advanced chimeric antigen receptor T-cell (CAR-T) therapies for hematological malignancies and solid tumors, as well as mesenchymal stem cell (MSC) treatments for orthopedic conditions. CBMG operates large-scale, GMP-compliant manufacturing facilities in Shanghai and Wuxi, China, and maintains a strategic corporate presence in the United States. Notably, the company partnered with Novartis to manufacture the CAR-T therapy Kymriah in China and has established collaborations with AstraZeneca for solid tumor programs. Formerly listed on NASDAQ, CBMG was taken private in 2021 by a consortium of investors to accelerate its clinical development and commercialization efforts.